THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
发明人:
Edward Paul HASTY,Vivienne REBEL,Xiaowen ZHANG
申请号：
US16756702
公开号：
US20200239969A1
申请日:
2018.10.16
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.
